Net cash swung to $15.3m net debt as FCF collapsed to $2.0m

Operating cash flow dropped 67% to $9.8m while capex stepped up 169% to $7.7m, compressing free cash flow before leases to $2.0m from $26.7m. Cash on hand fell 97.5% to $0.15m and gross borrowings rose from $3.4m to $15.4m, swinging the group from a $2.5m net cash position to roughly $15.3m of net debt. Total equity declined 13.3% to $58.0m.

NPAT fell 60.5% to $7.85m. The effective tax rate moved only marginally (28.7% versus 28.1% prior), so the operating read tracks PBT cleanly. EBITDA fell to $18.2m from $34.0m, and gross margin compressed 90 bps to 48.4%. H1FY23 contributed 74.9% of full-year NPAT, implying an H2 NPAT run-rate of about $2.0m versus $5.9m in H1.

OCF/EBITDA fell to 53.6% from 86.9%, and pre-lease FCF of $2.0m covered only 25.6% of NPAT — a sharp departure from FY22 when FCF was 1.3x NPAT. This matters because the gap between reported NPAT and actual cash generation is what is consuming the cash buffer and forcing the borrowing step-up; the historical baseline for inventory and debtor days remains within range, so the conversion gap sits in operating performance and reinvestment, not working capital.

Payout ratio versus pre-lease FCF is suppressed because the source-backed cash-dividend bridge is unavailable.

Leverage rebuilt off a low base. Gross borrowings rose more than 4x and cash all but disappeared, taking net debt/EBITDA to 0.8x from a net-cash position. The absolute leverage is moderate, but the speed of the swing — combined with falling equity and a 169% capex increase — is what changes the financial-flexibility read.

Annolyse's historical baseline puts revenue growth of -9.4% below the 3-period normal range (mean 31.7%) and NPAT growth of -60.5% below the normal range — both inflated by COVID-period comparisons, but still framing FY23 as a clear reset rather than a one-period stumble. PBT margin at 6.3% and NPAT margin at 4.5% remain within the supplied historical range, so the margin level itself is not unprecedented.

The H1/H2 split is unfavourable: H1 carried 74.9% of NPAT and 63.2% of EBITDA. If that exit pace persists, the FY24 anchor sits materially below the FY23 average — which matters because dividend and capex settings need to be re-tested against the lower base, not the reported full-year figure.

The effective tax rate moved only 0.6pp, the PBT–NPAT growth gap is 0.1pp, and there is no disclosed discontinued operation or one-off item. The earnings decline is operating in nature: lower revenue, 90 bps of gross-margin compression, and management's own commentary cites diseconomies of scale on lower volume.

Cash quality, however, weakened materially. The 33-percentage-point fall in OCF/EBITDA, the 169% capex step-up, the implied $2.0m H2 NPAT run-rate, and the swing from net cash to net debt all indicate the headline $18.2m EBITDA overstates the cash earnings the business is currently producing. ROE fell to 13.5% from 29.9% — still within the supplied historical range, but the trajectory is consistent with the cash and leverage signals rather than offsetting them. The reported result is therefore lower quality than the EBITDA figure suggests, with reinvestment intensity and volume deleverage both working against conversion.

This briefing cannot assess post-balance-date trading or subscriber/order trends, because no FY24 trading update or forward guidance is included in the supplied release.